Supplements and drugs

Labomar takes over Finland's Pharmia and grows in Northern European markets

It is the sixth acquisition for the Treviso-based company, which consolidates its international presence in nutraceuticals and medical devices

2 October 2025

3' min read

Translated by AI

Versione italiana

Key points

Growth
Strategy
The path

3' min read

Translated by AI

Versione italiana

Labomar scores its fifth acquisition in six years and acquires Finland's Pharmia Holding Oy, one of Europe's leading specialists in the development and production of food supplements, drugs and medical devices for third parties, with roots in Finland, Sweden, Denmark and Norway.

The transaction was finalised on 25 September and provides for Pharmia's current management to remain within the company, continuing to hold 2.15% of the company's capital.

Growth

The Italian company based in Istrana, Treviso, which is internationally active in the nutraceutical sector and specialises in the research, development and third-party production of food supplements, drugs, medical devices, foods for special medical purposes and cosmetics, took over 97.85% of the Finnish company founded in 1993, which now employs 85 people at its headquarters in Tuusula, a few kilometres from Helsinki Airport, and operates an integrated production site of 5,000 m², with an annual capacity of around 485 million tablets and capsules and 37,000 litres of liquids.

Pharmia Holding Oy counts on a 2024 turnover of EUR 20 million, with further visible growth in 2025, and a leading position in the Nordic countries with a strong know-how in the development of probiotics and medical devices; the company steadily invests 5% of its turnover in research and development, continuing to strengthen its operational efficiency and confirming itself as a strategic partner for numerous international players.

The strategy

The acquisition is part of the Labomar Group's growth strategy, which has always been focused on innovation, the development of advanced health solutions, and a diversified global presence. The entry of Pharmia Holding Oy," explains Laboram in a note, "will allow the company to continue to expand its competencies in research and development, particularly in medical devices and probiotics, and to benefit from a privileged position in a geographic area with high potential". The expansion into the Nordic market will also 'enable Labomar to consolidate its international presence in nutraceuticals and medical devices, expanding its customer base and generating new synergies in terms of innovation and product development'.

"Welcoming Pharmia into our Group is a source of great satisfaction and represents an important step in our vision of international growth," comments Walter Bertin, founder and managing director of Labomar. "We meet a team that shares our approach to innovation and quality, and that allows us to strengthen ourselves in a market full of opportunities, in which we will be able to build lasting relationships with the main players and accompany them towards increasingly advanced solutions. Pharmia's solid management structure and production capacity will also enable us to rapidly integrate activities and accelerate the development path we are tracing at European level'. And Petteri Laaksomo, CEO of Pharmia Holding Oy, adds: "This transaction represents a key strategic step in our mission to consolidate our presence in the Nordic region and further strengthen our competencies in the development of high-quality nutraceuticals and medical devices. Labomar's excellence and values are fully integrated with our own".

The route

With the backing of Charterhouse Capital Partners, Laboma continues a path of growth by external lines initiated in 2019 with the acquisition of Importfab (now Labomar Canada) which operates in the North American pharmaceutical, cosmetic and nutraceutical market, in 2020 of the Welcare Group, based in Orvieto, Umbria and specialising in medical devices for the prevention, hygiene and treatment of skin infections and lesions, of Labiotre, based in Tavarnelle Val di Pesa in Tuscany and dedicated to the production of plant extracts and supplements food in softgels, and finally Laboratorios Entema, a company based in Barcelona specialised in the contract production of cosmetics, medical devices and supplements food.